Fold №24 — Semax Phe-4 → 4-fluoro-Phe: MC4R Selectivity Tuning

Verdict: DISCARDED | Peptide: Semax (MEHFPGP) | Class: Cognitive | Target: MC4R

Mechanism of Action (Background)

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension, originally developed as a neuroprotective and nootropic agent. Its documented mechanisms are pleiotropic: upregulation of BDNF and NGF via TrkB/C signaling, modulation of dopaminergic and serotonergic neurotransmission, copper chelation through the Met-Glu-His N-terminal triad, anti-inflammatory cytokine regulation, and recently described effects on the USP18/ubiquitination pathway. Its structural heritage from ACTH(4-10) implies a melanocortinergic lineage — the His-Phe dyad (positions 3-4) is a remnant of the canonical His-Phe-Arg-Trp (HFRW) pharmacophore central to MC receptor binding across α-MSH and ACTH analogs — but no published study directly demonstrates Semax binding to, or functional agonism at, any MC receptor subtype (MC1R–MC5R) at defined pharmacological concentrations.

Critically, Semax lacks the Arg and Trp residues of the HFRW tetrapeptide that are widely considered essential for high-affinity MCR engagement. The C-terminal Pro-Gly-Pro extension is a structural departure from canonical melanocortin ligands and may impose conformational constraints that further limit HFRW-mode docking.

Modification Hypothesis (What We Tested)

Fold №24 substituted Phe-4 with 4-fluoro-phenylalanine (4F-Phe), yielding MEH(4F-F)PGP. The hypothesis: para-fluorination would invert the aromatic ring quadrupole moment and modestly increase lipophilicity, exploiting small differences in MC4R vs. MC1R/MC3R/MC5R transmembrane pocket residue identity (e.g., MC4R Ile-194 vs. MC1R Met-128) to bias engagement toward MC4R. The fluorine was predicted to preserve aromatic geometry and the His-Phe pharmacophoric core while fine-tuning subtype selectivity — a well-precedented strategy in fluorinated amino acid medicinal chemistry for GPCR ligands.

This approach is notably distinct from the three most recent cognitive-peptide folds in this lab. Fold №1 (Semax N-terminal acetylation, REFINED) targeted metabolic stability without presupposing a specific receptor mechanism. Folds №8 and №18 on the structurally related Selank (TKPRPGP) pursued proteolytic resistance via C-terminal amidation (PROMISING) and Gly-6 N-methylation (PROMISING) respectively. Fold №24 is the first in this series to pursue receptor subtype selectivity — and consequently the first to require a validated receptor engagement premise as its foundation.

Why the Prediction Was Uninformative (Technical Analysis)

The structural prediction pipeline returned superficially encouraging metrics: pLDDT 0.83, pTM 0.84, ipTM 0.96. These values suggest the model found a stable, confident pose for the modified heptapeptide complex. The heuristic peptide profile is unremarkable: aggregation propensity 0.0, stability score 0.80, moderate BBB penetration estimate (0.46), short half-life (~15–45 min) — consistent with native Semax and not materially altered by single-position ring fluorination.

The DISCARDED verdict is not a failure of the structural prediction tools; it is a failure of the biological premise. Three issues render the output uninformative:

1. No baseline MCR affinity for Semax exists. Zero published binding data (Ki, IC50, Kd) for Semax at any MCR subtype has been reported. Predicting a selectivity shift at MC4R relative to other subtypes is meaningless if the scaffold does not demonstrably bind MC4R in the first place. The Boltz-2 affinity module returned no values, consistent with this null.

2. Semax lacks the canonical HFRW pharmacophore. The full His-Phe-Arg-Trp tetrapeptide is required for high-affinity MCR engagement. Semax retains only the HF dyad; the Arg and Trp residues are absent. The structure prediction algorithm can model a conformation, but it cannot compensate for a missing pharmacophoric foundation. High pLDDT on a heptapeptide does not validate receptor contact geometry.

3. The Pro-Gly-Pro tail is a confounding structural variable. No published structural or docking study has characterized how the C-terminal Pro-Gly-Pro extension of Semax affects projection of the His-Phe core into an MCR transmembrane pocket. The selectivity logic borrowed from α-MSH analog fluorination studies may not transfer to this scaffold.

The Chai-1 agreement metric returned None, and the predicted binding change was None — the pipeline itself signaled no reliable interaction signal, consistent with the DISCARDED verdict.

What This Tells Us (Negative Results Are Data)

This fold meaningfully demarcates the epistemic boundary of Semax's current mechanistic evidence base. The DISCARDED outcome rules out the possibility of making an informative in silico statement about MC4R subtype selectivity for the Semax scaffold given current tools and current literature. This is not a trivial result:

• It confirms that structural confidence scores alone (pLDDT, pTM) do not constitute evidence of biological relevance. A well-folded pose in the absence of receptor engagement evidence is a confident answer to the wrong question.
• It establishes that selectivity optimization is downstream of affinity establishment. The Semax-MCR interaction, if it exists, needs characterization before SAR campaigns at Phe-4 have interpretable meaning.
• It highlights that Semax's copper-chelation activity (MEH triad) and its potential MCR activity are mechanistically orthogonal in the published literature, and should be treated as separate hypotheses requiring separate evidence chains.
• It suggests that the fluorinated phenylalanine substitution strategy — compelling as it is in the MCR field — is not transferable to Semax without receptor pharmacology data establishing Semax as a valid starting scaffold for MCR SAR.

Alternative Hypotheses to Test (Avoid the Failure Mode)

To productively build on the cognitive-peptide fold series without repeating this failure mode, the following alternatives are suggested:

1. Anchor to validated Semax mechanisms. Semax's copper-chelation activity via the MEH triad is well-characterized. A fold exploring His-3 → methylated-His or other N-terminal modifications to tune Cu(II) coordination geometry would have tractable, evidence-grounded predictions.

2. Pursue DPP-IV resistance at the His-Phe bond. The His-Phe dipeptide (positions 3-4) is a plausible DPP-IV cleavage site. Alpha-methyl phenylalanine at position 4 (rather than para-fluoro) would directly test metabolic resistance without requiring a receptor-binding premise — analogous to the DPP-IV resistance logic explored in adjacent folds in this lab.

3. If MC4R selectivity is the goal, choose a scaffold with established MCR affinity. MT-II, SHU9119, or cyclic MSH analogs all have published MCR binding data. Para-fluorination of the Phe in those scaffolds would have a defensible SAR context.

4. Extend the proteolytic resistance thread. Folds №8 (Selank C-terminal amidation, PROMISING) and №18 (Selank Gly-6 N-methylation, PROMISING) represent the strongest signal in this cognitive series. An analogous Pro-7 amidation or N-terminal modification of Semax — beyond the Fold №1 acetylation (REFINED) — may yield more actionable predictions by targeting the well-characterized Pro-Gly-Pro metabolic vulnerability.

All predictions are in silico only. No wet-lab validation has been performed. This report does not constitute medical advice.